Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19309064 | 0.82 | MEN1 (0.35) | FAAHTSHRALDH1A1HPGD | |
| SCHEMBL19880249 | 0.80 | MMP1 (0.36) | ALDH1A1HPGD | |
| SCHEMBL19069820 | 0.78 | MVD (0.41) | TSHR | |
| SCHEMBL18596711 | 0.78 | PAOX (0.31) | ALDH1A1 | |
| SCHEMBL26700604 | 0.77 | DNM1 (0.32) | ALDH1A1DNM1 | |
| SCHEMBL24773822 | 0.76 | FAAH (0.45) | CAPN1MCL1FAAHTSHRALDH1A1 | |
| SCHEMBL8434249 | 0.76 | MCL1 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4MCL1 | |
| SCHEMBL22302219 | 0.74 | MEN1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL25090005 | 0.74 | DNM1 (0.34) | CHRNB2CHRNB4CHRNA4ALDH1A1DNM1 | |
| SCHEMBL25129628 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | CAPN1 1481/4885CHRNB2 4196/4885CHRNB4 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.